Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03891979 | Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma | withdrawn | Phase 4 | 0 | NYU Langone HealthOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02570529 | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy | withdrawn | Phase 4 | 0 | Yonsei UniversityOTHER | 0 | Jan 29, 2019 | clinicaltrials |
| NCT01401387 | Pancreatic Enzyme Suppletion in Pancreatic Cancer(EPC) | withdrawn | Phase 4 | 0 | Foundation for Liver ResearchOTHER | 1 | Feb 22, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jun 26, 2020source: clinicaltrials